Media & Press
Ron Lanton III, Esq., Senior Partner at Lanton, Lanton & Sosa Law, provides legal and policy commentary to national and international news outlets covering healthcare, pharmaceuticals, biotechnology and government affairs.
Selected independent coverage
Fierce Biotech | November 10, 2026
‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire
Commentary on proposed outbound investment restrictions, pharmaceutical licensing, joint ventures and biotech financing.
Pink Sheet | October 21, 2026
USTR Investigation Into German Drug Pricing: Who Could Be Next?
Analysis of U.S. trade policy and potential implications for European pharmaceutical markets. Related LL&S analysis.
Reuters | September 22, 2026
European drugmakers call for faster trials, more spending to compete with US, China
Commentary on pharmaceutical investment, launch decisions and U.S. policy.
Reuters | March 31, 2026
Drugmakers delay some European launches with a wary eye on Trump’s pricing policies
Discussion of drug pricing uncertainty, market access and investor considerations.
APM Market Access
Publisher coverage: U.S. most-favored-nation drug pricing and launch sequencing
Leerink Partners
What Happens When Drug Pricing Meets Trade Policy? A Conversation with Ron Lanton
Industry publications and interviews
Explore Ron's BioPharm International author page, The Ron Lanton Report and the firm's Insights.
Media inquiries
For interviews or legal commentary, contact Lanton, Lanton & Sosa Law.